Navigation Links
Aeterna Zentaris Receives Orphan-Drug Designation from the FDA for AEZS-108 in Ovarian Cancer
Date:5/6/2010

n cancer is one of the most common gynaecologic malignancies and the fifth most frequent cause of cancer death in women, with most of the cases occurring in women between 50 and 75 years of age. Overall, ovarian cancer accounts for 4% of all cancer diagnoses in women and 5% of all cancer deaths. Approximately 26,000 new cases and 17,000 deaths from this disease are estimated in the European community every year (Source: Gynaecologic Oncology 2004; 92:819-26). The National Cancer Institute estimates that in 2009, in the United States alone, there were 21,550 news cases of ovarian cancer and 14,600 related deaths.

About AEZS-108

AEZS-108 represents a new targeting concept in oncology using a cytotoxic peptide conjugate which is a hybrid molecule composed of a synthetic peptide carrier and a well-known cytotoxic agent, doxorubicin. The design of this product allows for the specific binding and selective uptake of the cytotoxic conjugate by LHRH-receptor-positive tumors. The binding of AEZS-108 to cancerous cells that express these receptors results in its accumulation and preferential uptake in the malignant tissue.

About Aeterna Zentaris Inc.

Aeterna Zentaris Inc. is a late-stage drug development company specialized in oncology and endocrine therapy. News releases and additional information are available at www.aezsinc.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements invol
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... South San Francisco, CA (PRWEB) April 16, 2015 ... it is scheduled to report first quarter results on ... Following the announcement, Cytokinetics’ senior management will host a ... operational and financial results and the company’s outlook for ... webcast and can be accessed from the homepage and ...
(Date:4/16/2015)... Proove Biosciences , Inc. is ... Contest for the 2015 BIO International Convention. Hosted ... International Convention will take place June 15-18 at the ... of BIO contest, industry leaders will be voting for ... conference. The community voting period began on April 14, ...
(Date:4/16/2015)... Morton Grove, IL (PRWEB) April 16, 2015 ... the American Association for Cancer Research (AACR) ... at the Pennsylvania Convention Center, starting Saturday, April 18, ... The AACR holds claim to title of the oldest ... several journals, provides fellowships and grants, and partners with ...
(Date:4/16/2015)... 2015 OncoTAb, Inc., ... Charlotte) spin-out company, announced today the appointment of ... as Chief Operating Officer (COO). Cooper brings to ... developing clinical diagnostic and biotechnology platforms in the ... Cooper’s extensive career transcends the field of medical ...
Breaking Biology Technology:Cytokinetics to Announce First Quarter Results on April 30, 2015 2Cytokinetics to Announce First Quarter Results on April 30, 2015 3Proove Bisociences to Participate in the Buzz of BIO at the 2015 BIO International Convention 2Proove Bisociences to Participate in the Buzz of BIO at the 2015 BIO International Convention 3Regis Technologies Joins American Association for Cancer Research Annual Meeting 2OncoTAb Names Dr. David L. Cooper as COO 2
... - up 26% over 2007, - Record revenues from minimally invasive products - $4.9 million - up ... ... Coolrail(TM) linear ablation device and ORLab(TM) mapping ... system, WEST CHESTER, Ohio, May 6 AtriCure, Inc.,(Nasdaq: ATRC ...
... May 6 Biomatrica, the leader in room,temperature biological ... company as Vice President of Sales and Marketing.,Biomatrica,s interim ... an integral part of the company and will continue ... Ms. Dowling brings fourteen years of sales and ...
... Cepheid (Nasdaq:,CPHD) announced today that the Company will present at the ... Conference on May 13 at 12:15 p.m. EDT ... Bank of America Healthcare Conference on May 14 at 3:40 p.m. ... Las Vegas, John Bishop, Chief Executive Officer, and Andrew Miller, ...
Cached Biology Technology:AtriCure Reports First Quarter 2008 Financial Results 2AtriCure Reports First Quarter 2008 Financial Results 3AtriCure Reports First Quarter 2008 Financial Results 4AtriCure Reports First Quarter 2008 Financial Results 5AtriCure Reports First Quarter 2008 Financial Results 6AtriCure Reports First Quarter 2008 Financial Results 7AtriCure Reports First Quarter 2008 Financial Results 8Trisha Dowling Joins Biomatrica as Vice President, Sales and Marketing 2Cepheid to Present at the Robert W. Baird Growth Stock Conference and the Bank of America Healthcare Conference 2
(Date:3/30/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/lc9bnl/global_gesture ... Gesture Recognition Market in Automotive Sector 2014-2018" report ... Global Gesture Recognition market in Automotive Sector to grow ... Gesture recognition is the ability of a ... an individual. Gesture recognition technology can be 2D-based or ...
(Date:3/24/2015)... , Mar. 24, 2015 Research and Markets ... of the "Global Iris Recognition Market 2015-2019" ... the Global Iris Recognition market to grow at a ... This report covers the present scenario and the ... the period 2015-2019. To calculate the market size, the ...
(Date:3/24/2015)... NexID Biometrics LLC, whose spoof-mitigation technology boosts protection ... beginning of shipments of version 2.0 of its industry ... in Potsdam, N.Y. , is making ... here today at the Walter E. Washington Convention Center. ... boosts the accuracy rate range to 96.5 to 99.5 ...
Breaking Biology News(10 mins):Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2
... 22, 2011) - An animal,s behavior is probably ... alike. Its behavior involves processes internal to the animalgenetics, ... and social surroundings. According to the book,s authors, "Animal ... is sparked when neurons fire in response to stimuli ...
... available in German . The ... career researchers in Germany have been chosen. The selection ... Foundation) and the German Federal Ministry of Education and ... male researchers for the Heinz Maier-Leibnitz Prize 2011. The ...
... Research Council (BBSRC) announces the signing of a Memorandum of ... and Technology (MOST) in Vietnam. This heralds the start of ... tolerance in the world,s most important staple food in the ... Funds of up to 350K are being made available by ...
Cached Biology News:New book on animal behavior provides integrated view 2Heinz Maier-Leibnitz Prizes 2011: Recognition and incentive for early career researchers 2Heinz Maier-Leibnitz Prizes 2011: Recognition and incentive for early career researchers 3Heinz Maier-Leibnitz Prizes 2011: Recognition and incentive for early career researchers 4Heinz Maier-Leibnitz Prizes 2011: Recognition and incentive for early career researchers 5UK-Vietnam collaboration to improve world's most important staple food 2UK-Vietnam collaboration to improve world's most important staple food 3
Mouse monoclonal antibody to UGT2B10 - UDP glucuronosyltransferase 2 family, polypeptide B10...
Mouse monoclonal antibody raised against a partial recombinant WDR5. NCBI Entrez Gene ID = WDR5...
Mouse polyclonal antibody raised against a partial recombinant COASY. NCBI Entrez Gene ID = 80347...
... SM-2 adsorbents are macroporous polystyrene beads for ... surface area for adsorbing organics of molecular ... The beads are useful for the adsorption ... for example, the removal of detergents such ...
Biology Products: